Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Works (43)

Improving reporting of infection events in clinical trials

Blood Advances
2024-11-26 | Journal article
DOI: 10.1182/bloodadvances.2024014102
Contributors: Heinz Ludwig; Nikhil C. Munshi; Evangelos Terpos; Noopur Raje; Philippe Moreau; Ajay Nooka
Source: check_circle
Crossref

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

Blood Cancer Journal
2024-10-21 | Journal article
DOI: 10.1038/s41408-024-01160-1
Contributors: Niels W. C. J. van de Donk; Nizar Bahlis; Luciano J. Costa; María-Victoria Mateos; Ajay K. Nooka; Aurore Perrot; Alfred L. Garfall; Pragya Thaman; Keqin Qi; Clarissa Uhlar et al.
Source: check_circle
Crossref

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma

Blood Advances
2024-09-24 | Journal article
DOI: 10.1182/bloodadvances.2024013461
Contributors: Heinz Ludwig; Nikhil C. Munshi; Evangelos Terpos; Ilvy Schweitzer; Noopur Raje; Philippe Moreau; Ajay Nooka
Source: check_circle
Crossref

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

Blood Cancer Journal
2024-09-13 | Journal article
DOI: 10.1038/s41408-024-01120-9
Contributors: Nisha S. Joseph; Jonathan L. Kaufman; Vilas A. Gupta; Craig C. Hofmeister; Madhav V. Dhodapkar; Lawrence H. Boise; Sara M. DiCamillo; Danielle Roberts; Ajay K. Nooka; Sagar Lonial
Source: check_circle
Crossref

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

British Journal of Haematology
2024-06 | Journal article
DOI: 10.1111/bjh.19386
Contributors: Ajay K. Nooka; Jonathan L. Kaufman; Cesar Rodriguez; Andrzej Jakubowiak; Yvonne Efebera; Brandi Reeves; Tanya M. Wildes; Sarah A. Holstein; Larry D. Anderson, Jr; Ashraf Badros et al.
Source: check_circle
Crossref

Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3

British Journal of Haematology
2024-05 | Journal article
DOI: 10.1111/bjh.19346
Contributors: Mohamad Mohty; Nizar J. Bahlis; Ajay K. Nooka; Marco DiBonaventura; Jinma Ren; Umberto Conte
Source: check_circle
Crossref

Quadruplet therapy for newly diagnosed myeloma: Comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) vs daratumamab with RVD (DRVd) in transplant-eligible patients

2024-04-02 | Preprint
DOI: 10.21203/rs.3.rs-4138395/v1
Contributors: Nisha Joseph; Jonathan Kaufman; Vikas Gupta; Craig Hofmeister; Dhodapkar Madhav; Lawrence Boise; Danielle Roberts; Sara DiCamillo; Ajay Nooka; Sagar Lonial
Source: check_circle
Crossref

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study

Cancer
2024-03-15 | Journal article
DOI: 10.1002/cncr.35107
Contributors: Ajay K. Nooka; Cesar Rodriguez; María Victoria Mateos; Salomon Manier; Katherine Chastain; Arnob Banerjee; Rachel Kobos; Keqin Qi; Raluca Verona; Margaret Doyle et al.
Source: check_circle
Crossref

Glücksklee, the Quad, and High-Risk Myeloma

Journal of Clinical Oncology
2024-01-01 | Journal article
DOI: 10.1200/JCO.23.02017
Contributors: Ajay K. Nooka; Jonathan L. Kaufman; Sagar Lonial
Source: check_circle
Crossref

Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

Cancer
2023-12 | Journal article
DOI: 10.1002/cncr.34987
Contributors: Ajay K. Nooka; Adam D. Cohen; Hans C. Lee; Ashraf Badros; Attaya Suvannasankha; Natalie Callander; Al‐Ola Abdallah; Suzanne Trudel; Ajai Chari; Edward N. Libby et al.
Source: check_circle
Crossref

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Blood Cancer Journal
2023-12-20 | Journal article
DOI: 10.1038/s41408-023-00963-y
Contributors: Sara A. Scott; Ellen M. Marin; Kathryn T. Maples; Nisha S. Joseph; Craig C. Hofmeister; Vikas A. Gupta; Madhav V. Dhodapkar; Jonathan L. Kaufman; Sagar Lonial; Ajay K. Nooka
Source: check_circle
Crossref

Addressing the disparities: the approach to the African American patient with multiple myeloma

Blood Cancer Journal
2023-12-18 | Journal article
DOI: 10.1038/s41408-023-00961-0
Contributors: Manisha Bhutani; Brandon J. Blue; Craig Cole; Ashraf Z. Badros; Saad Z. Usmani; Ajay K. Nooka; Leon Bernal-Mizrachi; Joseph Mikhael
Source: check_circle
Crossref

Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction

JCO Oncology Practice
2023-09 | Journal article
DOI: 10.1200/OP.22.00781
Contributors: Laura F. Sun; Kathryn T. Maples; Kevin H. Hall; Yuan Liu; Yichun Cao; Nisha S. Joseph; Craig C. Hofmeister; Jonathan L. Kaufman; Madhav Dhodapkar; Ajay K. Nooka et al.
Source: check_circle
Crossref

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

Journal of Clinical Investigation
2023-08-01 | Journal article
DOI: 10.1172/JCI167629
Contributors: M. Hope Robinson; Nancy Y. Villa; David L. Jaye; Ajay K. Nooka; Alyssa Duffy; Samuel S. McCachren; Julia Manalo; Jeffrey M. Switchenko; Sierra Barnes; Sayalee Potdar et al.
Source: check_circle
Crossref

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma

Cancer
2023-07 | Journal article
DOI: 10.1002/cncr.34756
Contributors: Thomas G. Martin; Maria Victoria Mateos; Ajay Nooka; Arnob Banerjee; Rachel Kobos; Lixia Pei; Ming Qi; Raluca Verona; Margaret Doyle; Jennifer Smit et al.
Source: check_circle
Crossref

Cardiotoxicities of Cellular Therapies: A Practical Approach in a Sea of Uncertainty

JCO Oncology Practice
2023-06 | Journal article
DOI: 10.1200/OP.23.00154
Contributors: Anant Mandawat; Ajay K. Nooka
Source: check_circle
Crossref

Data from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.c.6551220
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Data from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.c.6551220.v1
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Supplementary Figures from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.22546614.v1
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Supplementary Figures from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.22546614
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Supplementary Table S1 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.22546611.v1
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Supplementary Table S1 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.22546611
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Supplementary Tables S2-S4 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.22546608.v1
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Supplementary Tables S2-S4 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

2023-04-04 | Preprint
DOI: 10.1158/2643-3230.22546608
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology
2023-03-10 | Journal article
DOI: 10.1200/JCO.21.02734
Contributors: Pieter Sonneveld; Asher Chanan-Khan; Katja Weisel; Ajay K. Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria-Victoria Mateos et al.
Source: check_circle
Crossref

Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Blood Cancer Discovery
2023-03-01 | Journal article
DOI: 10.1158/2643-3230.BCD-22-0173
Contributors: Maryam I. Azeem; Ajay K. Nooka; Uma Shanmugasundaram; Narayanaiah Cheedarla; Sayalee Potdar; Renee Julia Manalo; Alberto Moreno; Jeffrey M. Switchenko; Suneethamma Cheedarla; Deon Bryant Doxie et al.
Source: check_circle
Crossref

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

Blood Cancer Journal
2023-02-20 | Journal article
DOI: 10.1038/s41408-023-00801-1
Contributors: Kathryn T. Maples; Kevin H. Hall; Nisha S. Joseph; Craig C. Hofmeister; Vikas Gupta; Madhav V. Dhodapkar; Jonathan L. Kaufman; Ajay K. Nooka; Sagar Lonial
Source: check_circle
Crossref

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Journal of Clinical Oncology
2022-09-10 | Journal article
DOI: 10.1200/JCO.21.02257
Contributors: Ajay K. Nooka; Uma Shanmugasundaram; Narayana Cheedarla; Hans Verkerke; Venkata V. Edara; Rajesh Valanparambil; Jonathan L. Kaufman; Craig C. Hofmeister; Nisha S. Joseph; Sagar Lonial et al.
Source: check_circle
Crossref

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

Clinical Lymphoma Myeloma and Leukemia
2022-07 | Journal article
DOI: 10.1016/j.clml.2022.01.014
Contributors: AK Nooka; LJ Costa; CJ Gasparetto; PG Richardson; DS Siegel; A Chari; S Lentzsch; S Jagannath; J. Mikhael
Source: check_circle
Crossref

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Blood Cancer Journal
2022-04-13 | Journal article
DOI: 10.1038/s41408-022-00653-1
Contributors: Ajay K. Nooka; Jonathan L. Kaufman; Cesar Rodriguez; Andrzej Jakubowiak; Yvonne Efebera; Brandi Reeves; Tanya Wildes; Sarah A. Holstein; Larry D. Anderson, Jr; Ashraf Badros et al.
Source: check_circle
Crossref

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Cancer
2021-11-15 | Journal article
DOI: 10.1002/cncr.33809
Contributors: Sagar Lonial; Hans C. Lee; Ashraf Badros; Suzanne Trudel; Ajay K. Nooka; Ajai Chari; Al‐Ola Abdallah; Natalie Callander; Douglas Sborov; Attaya Suvannasankha et al.
Source: check_circle
Crossref

“I took the road less traveled, and that has made all the difference”: Making a case for high‐dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma

Cancer
2021-11-15 | Journal article
DOI: 10.1002/cncr.33825
Contributors: Ajay K. Nooka; Nisha S. Joseph; Sagar Lonial
Source: check_circle
Crossref

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

Blood Cancer Journal
2021-09-03 | Journal article
DOI: 10.1038/s41408-021-00545-w
Contributors: Karthik Ramasamy; Ajay Nooka; Hang Quach; Myo Htut; Rakesh Popat; Michaela Liedtke; Sascha A. Tuchman; Jacob Laubach; Cristina Gasparetto; Asher Chanan-Khan et al.
Source: check_circle
Crossref

Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design

Future Oncology
2021-06 | Journal article
DOI: 10.2217/fon-2020-1269
Contributors: Ajay K Nooka; Katja Weisel; Niels WCJ van de Donk; David Routledge; Paula Rodriguez Otero; Kevin Song; Hang Quach; Natalie Callander; Monique C Minnema; Suzanne Trudel et al.
Source: check_circle
Crossref

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Blood Cancer Journal
2021-06-18 | Journal article
DOI: 10.1038/s41408-021-00507-2
Contributors: Sundar Jagannath; Yi Lin; Hartmut Goldschmidt; Donna Reece; Ajay Nooka; Alicia Senin; Paula Rodriguez-Otero; Ray Powles; Kosei Matsue; Nina Shah et al.
Source: check_circle
Crossref

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Blood Cancer Journal
2021-05-26 | Journal article
DOI: 10.1038/s41408-021-00494-4
Contributors: Sagar Lonial; Ajay K. Nooka; Praneetha Thulasi; Ashraf Z. Badros; Bennie H. Jeng; Natalie S. Callander; Heather A. Potter; Douglas Sborov; Brian E. Zaugg; Rakesh Popat et al.
Source: check_circle
Crossref

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Blood Cancer Journal
2020-12-14 | Journal article
DOI: 10.1038/s41408-020-00393-0
Contributors: Yanyan Gu; Benjamin G. Barwick; Mala Shanmugam; Craig C. Hofmeister; Jonathan Kaufman; Ajay Nooka; Vikas Gupta; Madhav Dhodapkar; Lawrence H. Boise; Sagar Lonial
Source: check_circle
Crossref

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States

JCO Oncology Practice
2020-10 | Journal article
DOI: 10.1200/JOP.19.00639
Contributors: Yang Yu; Niquelle Brown Wade; Amie E. Hwang; Ajay K. Nooka; Mark A. Fiala; Ann Mohrbacher; Edward S. Peters; Karen Pawlish; Cathryn Bock; David J. Van Den Berg et al.
Source: check_circle
Crossref

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

Cancer
2019-09 | Journal article
DOI: 10.1002/cncr.32178
Contributors: Ajay K. Nooka; Nisha S. Joseph; Jonathan L. Kaufman; Leonard T. Heffner; Vikas A. Gupta; Charise Gleason; Lawrence H. Boise; Sagar Lonial
Source: check_circle
Crossref

Daratumumab in multiple myeloma

Cancer
2019-07-15 | Journal article
DOI: 10.1002/cncr.32065
Contributors: Ajay K. Nooka; Jonathan L. Kaufman; Craig C. Hofmeister; Nisha S. Joseph; Thomas L. Heffner; Vikas A. Gupta; Harold C. Sullivan; Andrew S. Neish; Madhav V. Dhodapkar; Sagar Lonial
Source: check_circle
Crossref

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

JCI Insight
2019-06-06 | Journal article
DOI: 10.1172/jci.insight.127807
Contributors: Jithendra Kini Bailur; Samuel S. McCachren; Deon B. Doxie; Mahesh Shrestha; Katherine Pendleton; Ajay K. Nooka; Natalia Neparidze; Terri L. Parker; Noffar Bar; Jonathan L. Kaufman et al.
Source: check_circle
Crossref

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites

Cancer
2018-11-15 | Journal article
DOI: 10.1002/cncr.31746
Contributors: Sarah Chehab; Chao Zhang; Elyse H. Panjic; Zhengjia Chen; Jonathan L. Kaufman; Sagar Lonial; Ajay Nooka; R. Donald Harvey
Source: check_circle
Crossref

High-risk Multiple Myeloma: Definition and Management

Clinical Lymphoma Myeloma and Leukemia
2017-07 | Journal article
DOI: 10.1016/j.clml.2017.02.018
Contributors: Nisha S. Joseph; Silvia Gentili; Jonathan L. Kaufman; Sagar Lonial; Ajay K. Nooka
Source: check_circle
Crossref
How many people are using ORCID?